drugset / Trial / NCT04821687

A Study to Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PD

NCT04821687

Phase 4 Completed 169 enrolled SK Chemicals Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

A Study to evaluate the add-on efficacy and safety of opicapone 50 mg or an extra dose of L-DOPA 100 mg for the treatment of wearing-off in patients with PD.

Timeline

Start
2021-06-17
Primary completion
2022-08-18
Completion
2022-08-18

Drugs

EvaluationDrugModalityDoseRoute
Comparator Madopar Tab. 125 or Perkin Tab. 25-100mg Unknown 100 mg
Subject Opicapone Small molecule 50 mg

Indications